Explore our related products: Reconstitution Solution 10x10ml and Reconstitution Solution 10x10ml
Questions remain around dosing, safety, and realistic expectations for BPC-157 therapy
BPC-157 is also not an FDA-approved treatment, and they've noted safety concerns surrounding this peptide, citing that it may contain impurities and may trigger an unwanted immune system response that could be dangerous
All eyes are watching BPC-157 because it can potentially mend many varied injuries and conditions with reduced healing time and with better results
In one single-center trial of 72 subjects using a controlled-adverse-environment model, the T4 eye drop did not meet its co-primary endpoints (ocular discomfort and inferior corneal staining) at the primary time point, but it did produce statistically significant improvements on several secondary endpoints, including central and superior corneal staining, with no adverse events reported
This makes it more accessible compared to other peptides that require injections